Table 2 Logistic regression analysis of the risk factors for 28-day mortality in patients with adequate empirical therapy
Variable | Univariate analysis | P | Multivariate analysis | P |
|---|---|---|---|---|
OR (95% CI) | OR (95% CI) | |||
Age | 1.00 (0.96-1.04) | .98 | ||
Male gender | 0.48 (0.14-1.76) | .27 | ||
Underlying disease | ||||
Solid organ malignancy | 1.22 (0.42-3.56) | .71 | ||
Hematologic malignancy | 2.33 (0.84-6.46) | .10 | ||
Structural lung disease | 0.25 (0.03-2.31) | .22 | ||
Neurologic disease | 0.21 (0.02-1.81) | .15 | ||
Congestive heart failure | 2.96 (0.26-34.42) | .39 | ||
Hemodialysis | 0.69 (0.06-8.05) | .77 | ||
Immunosuppression | 0.62 (0.20-1.93) | .41 | ||
McCabe score | ||||
Non-fatal | 0.57 (0.09-3.38) | .54 | ||
Ultimately fatal | 1.20 (0.24-6.11) | .83 | ||
Rapidly fatal | 1.0 (referent) | |||
APACHE II score | 1.04 (0.97-1.11) | .32 | ||
Pitt bacteremia score | 1.21 (0.96-1.51) | .10 | ||
CPIS | 1.06 (0.73-1.54) | .77 | ||
Type of pneumonia | ||||
Community-acquired | 1.00 (0.16-6.26) | .99 | ||
Healthcare-associated | 0.74 (1.12-4.73) | .75 | ||
Hospital- acquired | 1.02 (0.19-5.37) | .98 | ||
Ventilator-associated | 1.0 (referent) | |||
MDR-P. aeruginosa | 0.43 (0.08-2.30) | .32 | ||
Previous antibiotic therapy | 1.42 (0.53-3.86) | .49 | ||
Initial manifestation within 24 h | ||||
Sepsis | 0.36 (0.11-1.17) | .09 | 0.07 (0.01-0.49) | 0.008 |
Severe sepsis | 0.29 (0.07-1.21) | .09 | 0.13 (0.02-0.89) | 0.04 |
Septic shock | 1.0 (referent) | |||
Type of adequate empirical therapy | ||||
Monotherapy | 0.38 (0.14-1.06) | .06 | 0.05 (0.01-0.34) | 0.002 |
Combination therapy | 1.0 (referent) | |||